CN104706679A - Lacidophilin dispersible tablet for treating children diarrhea and preparation method thereof - Google Patents
Lacidophilin dispersible tablet for treating children diarrhea and preparation method thereof Download PDFInfo
- Publication number
- CN104706679A CN104706679A CN201310684383.4A CN201310684383A CN104706679A CN 104706679 A CN104706679 A CN 104706679A CN 201310684383 A CN201310684383 A CN 201310684383A CN 104706679 A CN104706679 A CN 104706679A
- Authority
- CN
- China
- Prior art keywords
- lactein
- dispersible tablet
- preparation
- lacidophilin
- starch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000007919 dispersible tablet Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 206010012735 Diarrhoea Diseases 0.000 title abstract description 4
- 229920002472 Starch Polymers 0.000 claims abstract description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 14
- 239000011734 sodium Substances 0.000 claims abstract description 10
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 10
- 239000008107 starch Substances 0.000 claims abstract description 9
- 235000019698 starch Nutrition 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims description 16
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000391 magnesium silicate Substances 0.000 claims description 16
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 16
- 235000019792 magnesium silicate Nutrition 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 10
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 9
- 239000005977 Ethylene Substances 0.000 claims description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 9
- 235000019890 Amylum Nutrition 0.000 claims description 8
- 208000019637 Infantile Diarrhea Diseases 0.000 claims description 7
- 239000011505 plaster Substances 0.000 claims description 7
- 150000002170 ethers Chemical class 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract description 4
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 2
- 206010000060 Abdominal distension Diseases 0.000 abstract 1
- 229940095564 anhydrous calcium sulfate Drugs 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- DGVMNQYBHPSIJS-UHFFFAOYSA-N dimagnesium;2,2,6,6-tetraoxido-1,3,5,7-tetraoxa-2,4,6-trisilaspiro[3.3]heptane;hydrate Chemical compound O.[Mg+2].[Mg+2].O1[Si]([O-])([O-])O[Si]21O[Si]([O-])([O-])O2 DGVMNQYBHPSIJS-UHFFFAOYSA-N 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- -1 polyoxylethylene Polymers 0.000 abstract 1
- 238000002156 mixing Methods 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 230000001476 alcoholic effect Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 239000007779 soft material Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 229920003081 Povidone K 30 Polymers 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 108010066657 azoreductase Proteins 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003984 copper intrauterine device Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- ZFRKQXVRDFCRJG-UHFFFAOYSA-N skatole Natural products C1=CC=C2C(C)=CNC2=C1 ZFRKQXVRDFCRJG-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a lacidophilin dispersible tablet for treating children diarrhea and a preparation method thereof. Components of the lacidophilin dispersible tablet comprise lacidophilin, compressible starch, low substituted hydroxypropy cellulose, anhydrous calcium sulfate, starch, MCC, sodium carboxy methyl starch, magnesium silicate hydrate micropowder and glycol polyoxylethylene ether. The preparation method comprises the following steps: a lacidophilin powder is directly mixed with or mixed with a disintegrating agent and other pharmaceutic adjuvants after addition of water; pelletizing is carried out; drying is carried out; and tabletting is carried out to prepare the dispersible tablet. The technology provided by the invention is simple. The dispersible tablet has high physical stability, is convenient to carry, is convenient for patients to take, and is especially suitable for symptoms such as children diarrhea, abdominal distension and the like.
Description
Technical field
The present invention relates to Chinese medicine technical field, particularly relate to a kind of lactein dispersible tablet being used for the treatment of infantile diarrhea and preparation method thereof.
Background technology
Lactein (Lacidophilin) is the powder that skimmed milk is made through lactobacillus fermentation, as the effective digester of one, is widely used in clinical because it has high safety (clinical practice has no untoward reaction).Lactein effectively can suppress the Growth and reproduction of pathogenic bacterium in intestinal; Reduce gut pH, thus suppress alkaliphilic bacterium growth and breeding; Prevent from accumulating the nuisances such as indole, scatol, phenol mercaptan in large intestine; By the effect of phosphoprotein and phosphatase, promote that Ruzhong casein digest absorbs; Adjustment enterokinesia treatment constipation, promotes gastric secretion, assists calcium absorption; Suppress the activity of p-glucuronic acid enzyme, azo reductase, nitroreductase in intestinal, thus prevent the conversion of carcinogen, the speed of growth of inhibition tumor cell, strengthen the immunologic function of human body.Its principal indication is: dyspepsia, inappetence, the abnormal mouldy abdominal distention, diarrhoea, enteritis, irritable colon syndrome etc. caused of enteral.Prevention canceration and ring alkali amide share treatment gastric cancer remarkable synergism.It is the common medicine of infantile diarrhea.
At present, the preparation of lactein has conventional tablet (chewable tablet), powder and granule, due to lactein, there is easy moisture absorption and meet the characteristic of water thickness, make lactein ordinary tablet not easy disintegrating in water, and powder and granule are in production, packaging, transport and stability etc., and all comparatively tablet is poor, and be unfavorable for that children's swallows.
Summary of the invention
Technical problem to be solved by this invention is, a kind of lactein dispersible tablet being used for the treatment of infantile diarrhea and preparation method thereof is provided, relative to ordinary preparation and preparation method, its simple process, gained dispersible tablet have physical stability high, be convenient for carrying and facilitate patients, be specially adapted to the symptom such as infantile diarrhea, abdominal distention.
In order to solve the problems of the technologies described above, the invention discloses a kind of lactein dispersible tablet being used for the treatment of infantile diarrhea, its composition has lactein, amylum pregelatinisatum, low-substituted hydroxypropyl cellulose, anhydrous dead plaster, starch, MCC, carboxymethylstach sodium, hydrated magnesium silicate micropowder, ethylene polyethenoxy ether.
The amount ranges of wherein said lactein dispersible tablet is respectively lactein 45 ~ 75%, amylum pregelatinisatum 5 ~ 32.1%, low-substituted hydroxypropyl cellulose 5 ~ 25.6%, dead plaster 1.5 ~ 10%, starch 2.7 ~ 11.9%, MCC1.3 ~ 48%, carboxymethylstach sodium 5.1 ~ 18.7%, hydrated magnesium silicate micropowder 0.2 ~ 1.1%, ethylene polyethenoxy ether 1.3 ~ 8.3%.
The invention also discloses the preparation method of lactein dispersible tablet simultaneously, be specially:
Lactein powder is directly mixed with disintegrating agent and other pharmaceutic adjuvants, granulates, dry, tabletting, obtained dispersible tablet.Described disintegrating agent refers to ethylene polyethenoxy ether class.
The preparation method of lactein dispersible tablet, by lactein in advance with the mass ratio of water or other solvent and lactein for after 1.1:3.9 ~ 3.2:4.8 carries out pretreatment, powder mixes with suitable disintegrating agent and other pharmaceutic adjuvants, granulate, dry, tabletting, obtained dispersible tablet.
The present invention is compared with existing lactein preparation (chewable tablet, granule, powder), advantage is: can fater disintegration in water, both there is the feature that tablet is easy to carry, physical stability is high, have again the convenience that granule is easy to take concurrently, be convenient to old man, the patient of child and dysphagia takes.
Detailed description of the invention
Embodiment 1
Lactein pretreatment
| Composition | Consumption |
| Lactein | 200g |
| Water | 120g |
Preparation method: extracting lactic acid rhzomorph, adds water, mixing, dry, pulverize, and crosses 100 and sieves and get final product.
Embodiment 2
Lactein dispersible tablet composition and preparation 1
| Composition | Consumption g | Content % |
| Lactein | 400 | 46.5 |
| Amylum pregelatinisatum | 200 | 23.3 |
| Low-substituted hydroxypropyl cellulose | 200 | 23.3 |
| Dead plaster | 50 | 5.8 |
| Hydrated magnesium silicate micropowder | 10 | 1.1 |
| 70% alcoholic solution | In right amount |
Preparation method: extracting lactic acid rhzomorph (or through pretreatment) 4008, adds 200g amylum pregelatinisatum and 100g low-substituted hydroxypropyl cellulose, mixing, adds 70% alcoholic solution appropriate, soft material processed, 20 mesh sieve granules.Wet granular is added 50g dead plaster and the mixing of 100g low-substituted hydroxypropyl cellulose, dry, add appropriate hydrated magnesium silicate micropowder mixing, tabletting.Every sheet is containing lactein 0.2g or 0.4g.
Embodiment 3
Lactein dispersible tablet composition and preparation 2
| Composition | Consumption g | Content % |
| Lactein | 400 | 56.7 |
| Starch | 50 | 7.1 |
| MCC | 150 | 21.3 |
| Carboxymethylstach sodium | 100 | 14.2 |
| Hydrated magnesium silicate micropowder | 5 | 0.7 |
| The 2% PVP K30 solution that 80% alcoholic solution is made | In right amount |
Preparation method: extracting lactic acid rhzomorph (or through pretreatment) 400g, adds 150gMCC, 50g starch and 100g carboxymethylstach sodium, mixing, and it is appropriate to add the 2% PVP K30 solution made with 80% alcoholic solution, soft material processed, 20 mesh sieve granules.After wet grain drying 3, add appropriate hydrated magnesium silicate micropowder mixing, tabletting.Every sheet is containing lactein 0.2g or 0.4g.
Embodiment 4
Lactein dispersible tablet composition and preparation 3
| Composition | Consumption g | Content % |
| Lactein | 400 | 75 |
| MCC | 100 | 19.8 |
| Hydrated magnesium silicate micropowder | 5 | 1.0 |
| 5% macrogol 600 solution | In right amount |
Preparation method: extracting lactic acid rhzomorph (or through pretreatment) 400g, adds 5% ethylene polyethenoxy ether 6000 solution appropriate, soft material processed, 20 mesh sieve granules, dry, adds the mixing of 100gMCC and 5g hydrated magnesium silicate micropowder, tabletting.Every sheet is containing lactein 0.2g or 0.4g.
Embodiment 5
Lactein dispersible tablet composition and preparation 4
| Composition | Consumption g | Content % |
| Lactein | 400 | 56.3 |
| Amylum pregelatinisatum | 100 | 14.1 |
| Low-substituted hydroxypropyl cellulose | 100 | 14.1 |
| Dead plaster | 100 | 10 |
| Hydrated magnesium silicate micropowder | 10 | 1.1 |
| 70% alcoholic solution | In right amount | |
| 5% PVP K30 solution ethanol solution | In right amount |
Preparation method: extracting lactic acid rhzomorph (or through pretreatment) 400g, adds 100g amylum pregelatinisatum and 100g low-substituted hydroxypropyl cellulose, mixing, adds 70% alcoholic solution appropriate, soft material processed, 20 mesh sieve granules; Get 100g carboxymethylstach sodium simultaneously, with 5% PVP K30 alcoholic solution soft material, 20 mesh sieve granules, dry.Two kinds of granules are merged, adds appropriate hydrated magnesium silicate micropowder mixing, tabletting.Every sheet is containing lactein 0.2g or 0.48g
Embodiment 6
Lactein dispersible tablet composition and preparation 5
| Composition | Consumption g | Content % |
| Lactein | 400 | 52.6 |
| MCC | 250 | 32.9 |
| Low-substituted hydroxypropyl cellulose | 100 | 13.2 |
| Hydrated magnesium silicate micropowder | 10 | 1.3 |
Preparation method: extracting lactic acid rhzomorph (or through pretreatment) 4C) 0g, add 250gMCC, 1009 low-substituted hydroxypropyl celluloses, mixing, add 70% alcoholic solution appropriate, soft material processed, 20 mesh sieve granules, dry, add appropriate hydrated magnesium silicate micropowder mixing, tabletting.Every sheet is containing lactein 0.2g or 0,4g.
Embodiment 7
Lactein dispersible tablet composition and preparation 6
| Composition | Consumption g | Content % |
| Lactein | 400 | 71.4 |
| Macrogol 600 | 50 | 8.9 |
| Carboxymethylstach sodium | 100 | 17.9 |
| Hydrated magnesium silicate micropowder | 10 | 1.8 |
| Ethanol | In right amount |
Preparation method: get 50g ethylene polyethenoxy ether 6000, adds ethanol in proper amount solubilize, adds the lactein (or through pretreatment) of 400g, mixing, obtains dope, by dope 40 mesh sieve granules, drying, adds carboxymethylstach sodium and the mixing of hydrated magnesium silicate micropowder, tabletting.Every sheet is containing lactein 0.2g or 0.4g.
Embodiment 8
The mensuration of lactein dispersible tablet disintegration
Experimental technique: get the made lactein dispersible tablet of above-described embodiment two and each 6 of conventional tablet, be placed in the hanging basket glass tubing of lift disintegration tester respectively, starts disintegration tester and checks, observes and records each disintegrate complete required time.
Experimental result: each disintegrate complete required time (minute) is as table 7
Table 7 each disintegrate complete required time (minute)
Experiment conclusion: be limited to during the average disintegration of (1) lactein dispersible tablet 2 points 37 seconds, be less than 3 minutes; The disintegration time of lactein conventional tablet is then more than 10 minutes.
The above is only preferred embodiment of the present invention, and be not restriction the present invention being made to other form, any those skilled in the art may utilize the technology contents of above-mentioned announcement to be changed or be modified as the Equivalent embodiments of equivalent variations.But everyly do not depart from technical solution of the present invention content, any simple modification, equivalent variations and the remodeling done above embodiment according to technical spirit of the present invention, still belong to the protection domain of technical solution of the present invention.
Claims (6)
1. be used for the treatment of a lactein dispersible tablet for infantile diarrhea, it is characterized in that described lactein dispersible tablet comprises lactein, amylum pregelatinisatum, low-substituted hydroxypropyl cellulose, anhydrous dead plaster, starch, MCC, carboxymethylstach sodium, hydrated magnesium silicate micropowder, ethylene polyethenoxy ether.
2. lactein dispersible tablet as claimed in claim 1, is characterized in that the amount ranges of described lactein dispersible tablet is respectively lactein 45 ~ 75%, amylum pregelatinisatum 5 ~ 32.1%, low-substituted hydroxypropyl cellulose 5 ~ 25.6%, dead plaster 1.5 ~ 10%, starch 2.7 ~ 11.9%, MCC1.3 ~ 48%, carboxymethylstach sodium 5.1 ~ 18.7%, hydrated magnesium silicate micropowder 0.2 ~ 1.1%, ethylene polyethenoxy ether 1.3 ~ 8.3%.
3. the preparation method of lactein dispersible tablet as claimed in claim 1, is characterized in that lactein powder directly to mix with disintegrating agent and other pharmaceutic adjuvants, granulates, dry, tabletting, obtained dispersible tablet.
4. the preparation method of lactein dispersible tablet as claimed in claim 3, is characterized in that described disintegrating agent refers to ethylene polyethenoxy ether class.
5. the preparation method of lactein dispersible tablet as claimed in claim 1, to it is characterized in that lactein in advance with the mass ratio of water or other solvent and lactein for after 1.1:3.9 ~ 3.2:4.8 carries out pretreatment, mix with suitable disintegrating agent and other pharmaceutic adjuvants again, granulate, dry, tabletting, obtained dispersible tablet.
6. the preparation method of lactein dispersible tablet formulation as claimed in claim 5, is characterized in that described disintegrating agent refers to ethylene polyethenoxy ether class.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310684383.4A CN104706679A (en) | 2013-12-14 | 2013-12-14 | Lacidophilin dispersible tablet for treating children diarrhea and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310684383.4A CN104706679A (en) | 2013-12-14 | 2013-12-14 | Lacidophilin dispersible tablet for treating children diarrhea and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104706679A true CN104706679A (en) | 2015-06-17 |
Family
ID=53406724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310684383.4A Withdrawn CN104706679A (en) | 2013-12-14 | 2013-12-14 | Lacidophilin dispersible tablet for treating children diarrhea and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104706679A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106422068A (en) * | 2016-08-28 | 2017-02-22 | 臧玉梅 | Traditional Chinese medicine magnetic therapy band for adjuvant therapy of pediatric diarrhea |
| CN106901344A (en) * | 2017-03-16 | 2017-06-30 | 北京知蜂堂健康科技股份有限公司 | A kind of composition for alleviating stomachache stomachache and its application |
| CN111000243A (en) * | 2019-12-26 | 2020-04-14 | 山东龙力生物科技股份有限公司 | Application of composition of oligosaccharide and lactein in food and health products |
| CN113133979A (en) * | 2020-01-20 | 2021-07-20 | 亚宝药业太原制药有限公司 | A lactobacillus tablet with improved taste |
-
2013
- 2013-12-14 CN CN201310684383.4A patent/CN104706679A/en not_active Withdrawn
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106422068A (en) * | 2016-08-28 | 2017-02-22 | 臧玉梅 | Traditional Chinese medicine magnetic therapy band for adjuvant therapy of pediatric diarrhea |
| CN106422068B (en) * | 2016-08-28 | 2019-01-18 | 韩素亮 | A kind of Chinese medicine magnetic belt assisting in the treatment of baby diarrhea |
| CN106901344A (en) * | 2017-03-16 | 2017-06-30 | 北京知蜂堂健康科技股份有限公司 | A kind of composition for alleviating stomachache stomachache and its application |
| CN111000243A (en) * | 2019-12-26 | 2020-04-14 | 山东龙力生物科技股份有限公司 | Application of composition of oligosaccharide and lactein in food and health products |
| CN113133979A (en) * | 2020-01-20 | 2021-07-20 | 亚宝药业太原制药有限公司 | A lactobacillus tablet with improved taste |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104706679A (en) | Lacidophilin dispersible tablet for treating children diarrhea and preparation method thereof | |
| CN104107188A (en) | Application and preparation method of apple polysaccharides for regulating alteration of intestinal flora and relaxing bowel | |
| CN103689748B (en) | One has adjustment intestines and stomach function, the anti-washing drink treated constipation | |
| CN103751124A (en) | Preparation of lactobacillin dispersible tablet and its preparation method | |
| CN104706671A (en) | Infantile diarrhea treating lacidophilin dispersible tablet | |
| CN102068672A (en) | Medicinal composition | |
| CN102596206A (en) | Pharmaceutical composition for oral administration | |
| CN103520188B (en) | A kind of poultry compound antibacterial dry suspension and preparation method thereof | |
| CN104970168A (en) | Sweetend roll containing prebiotics | |
| CN105998036B (en) | One boar fowl compound sulfonamide Nitazoxanide soluble powder | |
| CN103238710A (en) | Food healthcare tea granules for protecting gastric mucosa | |
| CN107692236B (en) | Application of light calcium carbonate in preparation of food, health-care product or medicine | |
| CN103689487B (en) | Pomegranate peel and Chinese yam dispersible tablet and preparation method thereof | |
| CN103877036A (en) | Rapid disintegrant preparation composition of bismuth subsalicylate and preparing method thereof | |
| CN102488767B (en) | Compound composition for treating bacterial diarrhoea of livestock and poultry | |
| CN106071232A (en) | Improve the additive of pig appetite | |
| CN101703238B (en) | Sea-cucumber chitosan capsules and preparation method thereof | |
| CN105012256B (en) | It is a kind of to be used to treat pharmaceutical composition of intestines problem and preparation method thereof | |
| CN101450074A (en) | Composition capable of greatly improving gastrointestinal tract function and preventing and treating astriction | |
| CN1535697A (en) | Preparation of lactobacillin dispersion tablet and its preparation method | |
| Widjanarko et al. | Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats | |
| CN104173304A (en) | Lincomycin dispersible tablet | |
| CN101664425A (en) | Poplar flower effervescent granules for treating avian colibacillosis and preparation method thereof | |
| CN100531725C (en) | Compositions of diphenylheptanones and their uses | |
| CN107047990A (en) | Newborn feed for preventing and treating calf diarrhea |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20150617 |